Asprosin-driven metabolic-epigenetic rewiring attenuates mesenchymal stem cell senescence with therapeutic benefits for infarcted hearts

Key Points

• Asprosin rejuvenates mesenchymal stem cells, counteracting senescence effectively.
• This metabolic-epigenetic interplay showcases the potential for regenerative therapies targeting heart diseases.
• The study emphasizes the 'Glycolysis-Lactylation-Epigenetics' axis as a transformative strategy in treatment.
• Findings indicate that enhancing asprosin pathways may lead to significant therapeutic advancements.